ValuEngine lowered shares of Hill-Rom Holdings Inc (NYSE:HRC) from a buy rating to a hold rating in a research note issued to investors on Saturday, November 4th.
A number of other equities analysts also recently commented on the stock. Cantor Fitzgerald set a $86.00 price objective on shares of Hill-Rom Holdings and gave the stock a hold rating in a research note on Friday, July 28th. Zacks Investment Research upgraded shares of Hill-Rom Holdings from a sell rating to a hold rating in a research note on Monday, September 18th. BidaskClub cut shares of Hill-Rom Holdings from a strong-buy rating to a buy rating in a report on Monday, July 24th. Needham & Company LLC dropped their target price on shares of Hill-Rom Holdings from $95.00 to $93.00 and set a buy rating on the stock in a report on Friday, July 28th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $84.00 target price on shares of Hill-Rom Holdings in a report on Sunday, July 30th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $88.57.
Shares of Hill-Rom Holdings (NYSE HRC) opened at $76.93 on Friday. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.77 and a quick ratio of 1.34. Hill-Rom Holdings has a 1 year low of $52.58 and a 1 year high of $84.65. The company has a market cap of $5,055.03, a price-to-earnings ratio of 19.88, a P/E/G ratio of 1.63 and a beta of 1.19.
Hill-Rom Holdings (NYSE:HRC) last announced its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.05. The firm had revenue of $738.30 million during the quarter, compared to analyst estimates of $731.10 million. Hill-Rom Holdings had a net margin of 4.87% and a return on equity of 20.27%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.18 EPS. research analysts expect that Hill-Rom Holdings will post 4.26 earnings per share for the current year.
WARNING: “Hill-Rom Holdings Inc (HRC) Downgraded by ValuEngine” was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://weekherald.com/2017/11/15/hill-rom-holdings-inc-hrc-stock-rating-lowered-by-valuengine.html.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be given a dividend of $0.18 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.72 annualized dividend and a dividend yield of 0.94%. Hill-Rom Holdings’s dividend payout ratio is 36.18%.
In other Hill-Rom Holdings news, SVP Andreas G. Frank sold 3,940 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total value of $306,689.60. Following the sale, the senior vice president now owns 16,701 shares in the company, valued at $1,300,005.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Andreas G. Frank sold 6,870 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $77.48, for a total transaction of $532,287.60. Following the completion of the sale, the senior vice president now owns 16,701 shares in the company, valued at approximately $1,293,993.48. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.
Large investors have recently modified their holdings of the company. Independent Portfolio Consultants Inc. raised its stake in Hill-Rom Holdings by 171.5% during the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock worth $107,000 after buying an additional 849 shares during the last quarter. Seven Eight Capital LP bought a new position in Hill-Rom Holdings during the second quarter worth $127,000. Acrospire Investment Management LLC raised its stake in Hill-Rom Holdings by 43.4% during the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock worth $158,000 after buying an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Hill-Rom Holdings by 10.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock worth $175,000 after buying an additional 204 shares during the last quarter. Finally, Citigroup Inc. raised its stake in Hill-Rom Holdings by 21.1% during the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after buying an additional 433 shares during the last quarter. Institutional investors own 82.05% of the company’s stock.
About Hill-Rom Holdings
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.